Thetis Awarded Key Patent on HEALER Technology

BRANFORD, CT – (July 17, 2018) – Thetis Pharmaceuticals LLC, a privately-held biopharmaceutical company focused on gastrointestinal diseases, announced today that the USPTO has granted patent US  9,999,626 providing composition of matter protection for its IBD development candidates. The allowed claims include pharmaceutical compositions that are mineral amino-acid based derivatives of fatty acids with 16 […]

Thetis Receives $1.9 Million Fast-Track NIH Grant to Advance Novel IBD Drug Pipeline Toward Clinical Investigation

First-in-human studies targeted for 2019 BRANFORD, CT – (GlobeNewswire – May 23, 2018) – Thetis Pharmaceuticals, a biopharmaceutical company developing novel therapies for treatment of inflammatory bowel disease (IBD), today announced the receipt of a Fast-Track Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH). The award provides up to $1.9 […]

FDA & Industry Veteran Brian E. Harvey, MD, PhD, Joins Thetis Pharmaceuticals as Senior Medical Director

Former FDA GI Division Director and V.P. of U.S. Regulatory Strategy at Pfizer to Guide Clinical and Regulatory Development of Thetis IBD Programs BRANFORD, CT – (GlobeNewswire – May 7, 2018) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing first-in-class, immuno-resolving small molecule drugs to treat inflammatory bowel disease (IBD), announced today that Brian […]